KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aceptableProbabilidad implícita actual
Before 2028 92%Líder entre 5 opciones
Calidad del mercado
46 / 100
Baja calidadVolumen 24h
—
Liquidez
7,2 mil €
Liquidez mediaSpread
5.0 pt
Spread moderadoDatos de mercado
Actualizado hace 10 minutos
16 may 26, 2:30 UTC1 ene 27, 4:59 UTC
Tendencias
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
When will Compass Pathways submit a NDA for COMP360 psilocybin?
Kalshi[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiReglas
If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing before Jan 1, 2028, then the market resolves to Yes.
Mercados abiertos
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No+0.4pt97%
- Yes-0.4pt3%
- Volumen total
- 15,7 M €
- Volumen 24h
- 52,2 mil €
KALSHIMeasles cases in 2026?
- Above 4000+2.0pt99%
- Above 300099%
- Above 600061%
+2 resultados más
- Volumen total
- 870,4 mil €
- Volumen 24h
- 2,1 mil €
POLYMARKETNew pandemic in 2026?
- No-1.0pt93.1%
- Yes+1.0pt6.9%
- Volumen total
- 922,5 mil €
- Volumen 24h
- 1,8 mil €
KALSHICyclosporiasis cases reported in the US in 2026?
- Above 18k99%
- Above 6k99%
- Above 10k99%
+12 resultados más
- Volumen total
- 32,4 mil €
- Volumen 24h
- 1,3 mil €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No97%
- Yes+0.4pt3%
- Volumen total
- 1,6 M €
- Volumen 24h
- 933,9 €
KALSHIHealthcare AI adoption in September
- Above 43%87%
- Above 43.75%59%
- Above 45%14%
+4 resultados más
- Volumen total
- 810,1 €
- Volumen 24h
- 767 €
- FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
- Measles cases in U.S. in 2026?
- Measles cases in U.S. by September 30?
- What will the average number of measles cases be during Trump's term?
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Will the FDA approve any psychedelic substance for medical use this year?
- Pandemic in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- Ebola: new country confirmed before October 1?
Preguntas frecuentes
- ¿Cuáles son las probabilidades actuales de When will the FDA approve Compass Pathways' COMP360 Psilocybin??
- Kalshi cotiza Before 2028 al 92% a fecha de 11 de septiembre de 2026.
- ¿Cuándo se resuelve When will the FDA approve Compass Pathways' COMP360 Psilocybin??
- Está previsto que When will the FDA approve Compass Pathways' COMP360 Psilocybin? se resuelva el 1 de enero de 2027.
- ¿Cómo se liquida When will the FDA approve Compass Pathways' COMP360 Psilocybin??
- Kalshi liquida este mercado del siguiente modo: If the FDA approves COMP360 Psilocybin for Treatment-Resistant Depression for marketing the named outcome, then the market resolves to Yes.